CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.
Peter Martin
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Sin-Ho Jung
No relevant relationships to disclose
Jeffrey L. Johnson
No relevant relationships to disclose
Brandy Pitcher
No relevant relationships to disclose
Rebecca L. Elstrom
Employment or Leadership Position - Roche/Genentech
Nancy Bartlett
Research Funding - Celgene
Kristie A. Blum
No relevant relationships to disclose
Kristy L. Richards
Consultant or Advisory Role - Genentech
John Leonard
Consultant or Advisory Role - Celgene
Bruce D. Cheson
Consultant or Advisory Role - Celgene; Genentech